• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

接受培美曲塞联合顺铂治疗的非鳞状非小细胞肺癌患者外周血免疫相关基因表达与无进展生存期的相关性分析

PD-L1-negative Non-small-cell Lung Cancer Treated with Nivolumab Plus Ipilimumab during Maintenance Hemodialysis Results in Rapid Initial Progression Followed by a Long-lasting Response.

机构信息

Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan.

出版信息

Intern Med. 2024 Apr 1;63(7):985-988. doi: 10.2169/internalmedicine.2270-23. Epub 2023 Aug 9.

DOI:10.2169/internalmedicine.2270-23
PMID:37558475
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11045368/
Abstract

Nivolumab plus ipilimumab is one of the first-line treatments for advanced non-small-cell lung cancer (NSCLC), but the safety and efficacy in patients on hemodialysis (HD) is unclear. We herein report a patient with NSCLC on HD in whom nivolumab and ipilimumab were initiated. We observed general deterioration and enlarged lesions, followed by a long-term response. The patient developed secondary hypoadrenocorticism, an immune-related adverse event that was easily controlled. Nivolumab plus ipilimumab can be used safely for patients with NSCLC on HD. Long-term effectiveness can be observed after initial progression, so we should carefully assess the response.

摘要

纳武利尤单抗联合伊匹单抗是晚期非小细胞肺癌（NSCLC）的一线治疗方法之一，但血液透析（HD）患者的安全性和疗效尚不清楚。本文报告了一例 HD 患者接受纳武利尤单抗和伊匹单抗治疗的病例。我们观察到一般病情恶化和病灶增大，随后出现长期缓解。患者发生了继发性肾上腺皮质功能减退症，这是一种免疫相关的不良反应，很容易得到控制。纳武利尤单抗联合伊匹单抗可安全用于 HD 患者的 NSCLC。在最初进展后可观察到长期疗效，因此我们应仔细评估反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7016/11045368/692cf206ba96/1349-7235-63-0985-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7016/11045368/034464a42ffa/1349-7235-63-0985-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7016/11045368/692cf206ba96/1349-7235-63-0985-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7016/11045368/034464a42ffa/1349-7235-63-0985-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7016/11045368/692cf206ba96/1349-7235-63-0985-g002.jpg

相似文献

1
PD-L1-negative Non-small-cell Lung Cancer Treated with Nivolumab Plus Ipilimumab during Maintenance Hemodialysis Results in Rapid Initial Progression Followed by a Long-lasting Response.接受培美曲塞联合顺铂治疗的非鳞状非小细胞肺癌患者外周血免疫相关基因表达与无进展生存期的相关性分析
Intern Med. 2024 Apr 1;63(7):985-988. doi: 10.2169/internalmedicine.2270-23. Epub 2023 Aug 9.
2
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.CheckMate 227 研究第一部分：转移性非小细胞肺癌一线纳武利尤单抗联合伊匹木单抗治疗：日本患者 5 年结果
Int J Clin Oncol. 2023 Oct;28(10):1354-1368. doi: 10.1007/s10147-023-02390-2. Epub 2023 Aug 7.
3
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients.一线纳武利尤单抗联合伊匹单抗治疗晚期 NSCLC：CheckMate 227 亚组分析在亚洲患者中的结果。
ESMO Open. 2022 Feb;7(1):100394. doi: 10.1016/j.esmoop.2022.100394. Epub 2022 Feb 12.
4
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.纳武利尤单抗联合伊匹单抗对比化疗作为一线治疗用于 CheckMate 227 研究转移性非小细胞肺癌的 5 年生存结果。
J Clin Oncol. 2023 Feb 20;41(6):1200-1212. doi: 10.1200/JCO.22.01503. Epub 2022 Oct 12.
5
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.纳武利尤单抗联合伊匹单抗治疗晚期非小细胞肺癌。
N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.
6
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.CheckMate 227 研究部分 1：一线纳武利尤单抗联合伊匹木单抗治疗伴基线脑转移的转移性非小细胞肺癌患者的系统和颅内结局。
J Thorac Oncol. 2023 Aug;18(8):1055-1069. doi: 10.1016/j.jtho.2023.04.021. Epub 2023 May 3.
7
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.CheckMate 9LA 随机试验中，一线纳武利尤单抗联合伊匹单抗加化疗治疗转移性非小细胞肺癌的 4 年临床更新和治疗转换调整结局。
J Immunother Cancer. 2024 Feb 12;12(2):e008189. doi: 10.1136/jitc-2023-008189.
8
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.纳武利尤单抗联合伊匹单抗一线治疗晚期非小细胞肺癌（CheckMate 568）：程序性死亡配体 1 和肿瘤突变负荷作为生物标志物的结果。
J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20.
9
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.纳武利尤单抗联合伊匹单抗治疗高肿瘤突变负荷肺癌。
N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.
10
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.无驱动基因改变的IV期非小细胞肺癌的治疗：美国临床肿瘤学会生存指南
J Clin Oncol. 2022 Oct 1;40(28):3323-3343. doi: 10.1200/JCO.22.00825. Epub 2022 Jul 11.

本文引用的文献

1
Association Between Age and Survival Trends in Advanced Non-Small Cell Lung Cancer After Adoption of Immunotherapy.免疫治疗应用后老年晚期非小细胞肺癌患者生存趋势的相关性研究。
JAMA Oncol. 2023 Mar 1;9(3):334-341. doi: 10.1001/jamaoncol.2022.6901.
2
Effects of hepatic or renal impairment on the pharmacokinetics of immune checkpoint inhibitors.肝肾功能损害对免疫检查点抑制剂药代动力学的影响。
Am J Cancer Res. 2022 Nov 15;12(11):4892-4903. eCollection 2022.
3
Two cases of nivolumab plus ipilimumab therapy for dialysis patients with advanced bone metastasis from renal cell carcinoma.
两例纳武利尤单抗联合伊匹木单抗治疗晚期肾细胞癌骨转移行血液透析患者。
CEN Case Rep. 2023 May;12(2):237-241. doi: 10.1007/s13730-022-00753-8. Epub 2022 Nov 19.
4
Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.回顾针对单克隆抗体（mAbs）的现有转化药代动力学建模方法，以支持首次人体（FIH）剂量选择。
Int J Mol Sci. 2022 Oct 22;23(21):12754. doi: 10.3390/ijms232112754.
5
Successful Response to Nivolumab Plus Ipilimumab Therapy in a Hemodialysis Patient With Metastatic Renal Cell Carcinoma.纳武单抗联合伊匹木单抗治疗对一名患有转移性肾细胞癌的血液透析患者产生成功疗效。
Cancer Diagn Progn. 2021 Jul 3;1(3):207-211. doi: 10.21873/cdp.10028. eCollection 2021 Jul-Aug.
6
A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.阿替利珠单抗联合贝伐珠单抗治疗肝细胞癌的假性进展 1 例
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211058489. doi: 10.1177/23247096211058489.
7
Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma.三例血液透析患者转移性肾细胞癌接受纳武利尤单抗联合伊匹单抗治疗。
In Vivo. 2021 Nov-Dec;35(6):3585-3589. doi: 10.21873/invivo.12663.
8
Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis.纳武利尤单抗联合伊匹单抗在一名转移性透明细胞肾细胞癌伴去分化肉瘤样变和血液透析终末期肾病患者中的安全有效应用。
Cancer Treat Res Commun. 2021;27:100349. doi: 10.1016/j.ctarc.2021.100349. Epub 2021 Mar 10.
9
Safe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma.肾细胞癌透析患者安全使用伊匹单抗加纳武单抗。
IJU Case Rep. 2020 Oct 28;4(1):32-35. doi: 10.1002/iju5.12231. eCollection 2021 Jan.
10
Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature.探讨免疫检查点抑制剂在慢性肾衰竭中的知识差距：文献系统评价。
Crit Rev Oncol Hematol. 2021 Jan;157:103169. doi: 10.1016/j.critrevonc.2020.103169. Epub 2020 Nov 22.